PT  - JOURNAL ARTICLE
AU  - E.M. de Koff
AU  - D. van Baarle
AU  - M.A. van Houten
AU  - M. Reyman
AU  - G.A.M. Berbers
AU  - F. de Heij
AU  - M.L.J.N. Chu
AU  - E.A.M. Sanders
AU  - D. Bogaert
AU  - S. Fuentes
TI  - Microbiota development in early life mediates association between mode of delivery and vaccine responses
AID  - 10.1101/2021.09.01.21262898
DP  - 2021 Jan 01
TA  - medRxiv
PG  - 2021.09.01.21262898
4099  - http://medrxiv.org/content/early/2021/09/03/2021.09.01.21262898.short
4100  - http://medrxiv.org/content/early/2021/09/03/2021.09.01.21262898.full
AB  - The gut microbiota in early life, when critical immune maturation takes place, may influence the immunogenicity of childhood vaccinations. We assessed the association between mode of delivery, gut microbiota development in the first year of life, and mucosal antigen-specific immunoglobulin G (IgG) responses against pneumococcal and meningococcal conjugate vaccination at ages 12 and 18 months, respectively, in a prospective birth cohort of 120 infants. Birth by natural delivery was associated with higher IgG responses against both vaccines, which for the anti-pneumococcal IgG response could be explained by a gut microbial community composition with high abundances of Bifidobacterium and Escherichia coli in the first weeks of life. High E. coli abundance in the same period was also associated with higher anti-meningococcal IgG responses. Our results suggest that associations between mode of delivery and antibody responses to routine childhood vaccines are mediated by gut microbiota development.Competing Interest StatementThe authors have declared no competing interest.Clinical Protocols https://www.trialregister.nl/trial/3821 Funding StatementThis work was funded by the Netherlands Organization for Scientific Research, Chief Scientist Office/NHS Research Scotland, Spaarne Gasthuis, University Medical Center Utrecht, Dutch Ministry of Health, Welfare and Sport and the Strategic Program of the National Institute for Public Health and the Environment (SPR). No other external funding was received.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:METC Noord-Holland (M012-015, NTR3986), Dutch committee on research involving human subjectsAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesSequence data that support the findings of this study have been deposited in the NCBI Sequence Read Archive (SRA) database with BioProject ID PRJNA481243, and PRJNA555020. https://www.ncbi.nlm.nih.gov/bioproject/PRJNA481243/ https://www.ncbi.nlm.nih.gov/bioproject/?term=PRJNA555020